Archives
Cure SMA Scientific Advisory Board Highlights Findings from The 2013 SMA Research Group Meeting
Originally published on August 28, 2013. The Cure SMA Scientific Advisory Board (SAB) helps organize, select the content, and chair sessions at the Cure SMA […]
Read More ›Meet Newly Funded Cure SMA Researchers: Oscar Mayer, MD PhD and Vanessa Battista, MS
Originally published on September 10, 2013. Dr. Mayer and Ms. Battista were awarded funding by Cure SMA for one of four new clinical care focused […]
Read More ›Meet Newly Funded Cure SMA Researcher: Dr. Kathryn Swoboda
Originally published on September 17, 2013. Dr. Swoboda was awarded funding by Cure SMA for one of four Clinical Care focused projects. The project is […]
Read More ›Meet Newly Funded Cure SMA Researcher Dr. Timothy Lotze
Originally published on October 1, 2013. Dr. Timothy Lotze was awarded funding by Cure SMA for one of four new Clinical Care focused projects. The […]
Read More ›Meet Newly Funded Cure SMA Researcher Dr. Matthew A. Halanski
Originally published on September 25, 2013. Dr. Matthew Halanski was awarded funding by Cure SMA for one of four Clinical Care focused projects. The project […]
Read More ›Cure SMA Contributes Research Funding to Sixteen SMA Journal Articles in 2013
Originally published on December 30, 2013. Cure SMA is proud to have contributed funding to the research published in the following journal articles in 2013. […]
Read More ›Cure SMA Funds 25 Research Projects in 2013
Originally published on October 24, 2013. Cure SMA invests in four research areas: Basic Research, Drug Discovery, Clinical Research, and Care Research. Cure SMA has […]
Read More ›Trophos Completes Efficacy Study of Olesoxime in Patients with Spinal Muscular Atrophy
Originally published on November 5, 2013. Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served […]
Read More ›Isis Reports Follow-Up Data From Phase 1 Study In Children With Spinal Muscular Atrophy
Originally published on September 19, 2013. Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx […]
Read More ›Pfizer RG3039 Program for Spinal Muscular Atrophy Reaches Development Milestone
Originally published on September 4, 2013. Reaching the first milestone was triggered by completion of specific program activities and coincides with the successful completion of […]
Read More ›